fda label semaglutide naion warning 2025 Warns Novo Nordisk on Unreported Deaths Your diabetic patient on semaglutide

As always, we thank you for your continuing efforts to improve the health outcomes of our members

A realistic way to think about GLP-1 medications: They improve the environment around lipedema (not the diseased tissue itself) GLP-1 belongs in the category of supportive tools similar to anti-inflammatory diet, metabolic care, and mobility support

Always consult with a healthcare professional for personalized advice regarding the use of Qsymia

Retatrutides potential for greater weight loss and metabolic benefits, if it is FDA approved, makes it an exciting option, particularly for patients with severe obesity or those who have not responded well to other treatments